New hope for rare blood vessel disorders: everolimus trial launches
NCT ID NCT07477548
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests the drug everolimus in 67 people with vascular anomalies (abnormal blood vessels) that haven't responded to standard treatments. The goal is to shrink the lesions and improve symptoms. Participants take everolimus daily for 6 months, with doses adjusted by age and other medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Everolimus (a drug that blocks a protein called mTOR, which helps control cell growth)
- What this could lead to
- If it works, this could offer a new treatment option for people with severe vascular anomalies that haven't responded to other therapies.
- What could go wrong
- This is an early phase 2 trial with no control group, so results are uncertain. Everolimus can cause side effects like mouth sores, infections, and metabolic changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTERIOVENOUS MALFORMATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new questionnaire give patients a stronger voice in vascular malformation care?
- Can a cancer drug shrink birthmarks? bleomycin injections put to the test
- Electric pulses may boost a drug's power against painful vascular malformations
- Massive HHT registry aims to unlock secrets of rare bleeding disorder
- Electric shock therapy may shrink blood vessel birthmarks
- Brain AVM drug trial pulled before it began